Literature DB >> 21547381

Central inflammation versus peripheral regulation in multiple sclerosis.

L J Edwards1, B Sharrack, A Ismail, H Tumani, C S Constantinescu.   

Abstract

Th17 cells are a highly pro-inflammatory T-helper cell subset characterised by the expression of IL17. They have been implicated in a variety of allergic and autoimmune conditions. T-regulatory (Treg) cells, a subset of CD4 cells which express Foxp3, CD25, IL10 and TGFβ, can suppress the activity of Th17 cells. In this study, we show that the circulating levels of Th17 and Treg cells in peripheral blood are correlated; furthermore, the expression of the pro-inflammatory cytokine IL17 and the anti-inflammatory cytokine IL10 by CD4 cells are also correlated. However, we found no clear correlation between cerebrospinal fluid (CSF) IL10 and IL17 cytokine levels in MS, approaching a negative correlation at the time of relapse, and an overall negative correlation between CSF IL17 and TGFβ levels, suggesting a lack of central regulation of pro:anti-inflammatory balance in this demyelinating condition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547381     DOI: 10.1007/s00415-011-5973-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  38 in total

1.  Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

Authors:  S L Hauser; T H Doolittle; R Lincoln; R H Brown; C A Dinarello
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

2.  IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles.

Authors:  C Malmeström; B A Andersson; S Haghighi; J Lycke
Journal:  J Neuroimmunol       Date:  2006-04-19       Impact factor: 3.478

3.  The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients.

Authors:  Halina Bartosik-Psujek; Zbigniew Stelmasiak
Journal:  Clin Neurol Neurosurg       Date:  2005-12-15       Impact factor: 1.876

4.  Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients.

Authors:  H Bartosik-Psujek; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2004-10-12       Impact factor: 3.575

5.  Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation.

Authors:  Hania Kebir; Katharina Kreymborg; Igal Ifergan; Aurore Dodelet-Devillers; Romain Cayrol; Monique Bernard; Fabrizio Giuliani; Nathalie Arbour; Burkhard Becher; Alexandre Prat
Journal:  Nat Med       Date:  2007-09-09       Impact factor: 53.440

6.  Th17 and natural Treg cell population dynamics in systemic lupus erythematosus.

Authors:  Ji Yang; Yiwei Chu; Xue Yang; Di Gao; Lubing Zhu; Xinrong Yang; Linlin Wan; Ming Li
Journal:  Arthritis Rheum       Date:  2009-05

7.  Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients.

Authors:  Anton Vladić; Gordana Horvat; Stjepan Vukadin; Zvonimir Sucić; Sumski Simaga
Journal:  Cytokine       Date:  2002-10-21       Impact factor: 3.861

8.  T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

Authors:  Luca Durelli; Laura Conti; Marinella Clerico; Daniela Boselli; Giulia Contessa; Paolo Ripellino; Bruno Ferrero; Pierre Eid; Francesco Novelli
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

9.  Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.

Authors:  Prabhakar Putheti; Asa Pettersson; Mats Soderstrom; Hans Link; Yu Min Huang
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

10.  Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta.

Authors:  K Nakamura; A Kitani; W Strober
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

View more
  6 in total

1.  Progress in multiple sclerosis research in the last year.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neurol       Date:  2012-06-22       Impact factor: 4.849

2.  Regulation is no bad thing.

Authors:  Emma H Wilson
Journal:  Immunol Cell Biol       Date:  2017-04-25       Impact factor: 5.126

Review 3.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

4.  Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study.

Authors:  Ali Manouchehrinia; Laura J Edwards; Homayoun Roshanisefat; Christopher R Tench; Cris S Constantinescu
Journal:  BMJ Open       Date:  2015-05-20       Impact factor: 2.692

5.  miR-141 and miR-200a, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis.

Authors:  Reza Naghavian; Kamran Ghaedi; Abbas Kiani-Esfahani; Mazdak Ganjalikhani-Hakemi; Masoud Etemadifar; Mohammad Hossein Nasr-Esfahani
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

Review 6.  Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease.

Authors:  Michal A Rahat; Jivan Shakya
Journal:  Mediators Inflamm       Date:  2016-02-22       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.